Ask your doctor which option is best for you.
How is Somatuline Depot administered?
Somatuline Depot (lanreotide) is an injection that should be given by a healthcare professional (or HCP) every 4 weeks. Nurse Home Health Administration (NHHA) may be available for patients who are unable to receive their Somatuline Depot injections at the doctor’s office:
- Eligible patientsa can have a nurse visit their home or site of choice to administer their injections
- There is no cost to the patient for this option
NHHA must be requested by the doctor and the patient must be enrolled in IPSEN CARES®.
aAdditional terms and conditions apply. Please visit www.ipsencares.com for details.
As few as 7 doses a year for controlled patientsb,c
If your hormones and symptoms are controlledb,c, your doctor may offer to:
- Continue giving you the same dose, or
- Increase the dose to 120 mg and give you injections less often—every 6 or 8 weeks
b In patients whose acromegaly is controlled after 3 months of treatment. Controlled is defined as GH level from >1.0 ng/mL to ≤2.5 ng/mL, normalized IGF-1 level, and satisfactory management of clinical symptoms as determined by the healthcare provider. This dosing interval is based on controlled patients using 8-week dosing intervals after year 1.
c Patients who are controlled with Somatuline Depot 60 mg or 90 mg administered every 4 weeks can be considered for treatment with 120 mg administered every 6 or 8 weeks. GH and IGF-1 levels should be obtained 6 weeks after this change in dosing regimen to evaluate persistence of patient response. Continued monitoring of patients’ responses with dose adjustments for biochemical and clinical symptom control, as necessary, is recommended.
Patients receiving Somatuline® Depot administered once every 4 weeks
Patients receiving the Somatuline Depot 120-mg dose every 6 weeks
Patients receiving the Somatuline Depot 120-mg dose every 8 weeks
Redesigned in 2019 with you in mindd
Through a series of 4 studies between 2015 and 2017, Ipsen sought feedback from patients, nurses, and caregivers on the Somatuline Depot syringe. The syringe was then redesigned in 2019 based on this feedback.
Device not shown at actual size
Somatuline Depot is covered by most commercial insurance plans.
d Study Design: The Somatuline Depot delivery system was updated in 2019 to provide an improved ergonomic injection experience, based on user feedback. Through a series of 4 formative studies between 2015 and 2017, Ipsen sought feedback from patients, nurses, and caregivers on the design and functionality of updated delivery device prototypes. These culminated in a human factors validation study in 2017 in which the final delivery system prototype was tested to determine whether the product could be safely and effectively used by intended users in the intended use environment. Key changes between the previously marketed delivery system and the current delivery system are: an overcap to improve the ergonomics (and needle shield removal); plunger support for the current delivery system; and improved version of the needle safety system.